In its largest single-asset purchase ever, Takeda snaps up TYK2 drug [from SV portfolio company, Nimbus] for $4B upfront

Takeda is buying Nimbus’ late-stage TYK2 inhibitor, an oral drug for autoimmune diseases, for $4 billion in cash upfront. That sets Takeda up to compete with Bristol Myers Squibb, which got the first TYK2 inhibitor approval in September for psoriasis.